

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



3SBIO INC.

三生制药

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1530)

VOLUNTARY ANNOUNCEMENT

TPIAO RECEIVED MARKETING AUTHORIZATION FROM PIC/S MEMBER UKRAINE

The board of directors (the “**Board**”) of 3SBio Inc. (the “**Company**”) is pleased to announce that on June 24, 2016, the Company’s TPIAO, a 15,000 IU/ml injectable solution of recombinant human thrombopoietin (rhTPO), received marketing authorization No./15181/01/01 from the Ministry of Public Health of Ukraine for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. The authorization is valid for the entire territory of Ukraine until June 21, 2021. TPIAO will be marketed in Ukraine under the brand name Emaplag.

Ukraine is a member of the Pharmaceutical Inspection Co-operation Scheme (the “**PIC/S**”). PIC/S is a non-binding and informal co-operative arrangement between regulatory authorities in the field of Good Manufacturing Practice of medicinal products for human or veterinary use. PIC/S presently comprises 48 participating authorities from Europe, Africa, America, Asia and Australasia. Ukraine has a population of over 45 million and approximately 141,000 cancer cases were diagnosed in 2012⁽¹⁾. The marketing authorization received from a PIC/S member will help the Company’s international registration in other PIC/S members and its further expansion into the regulatory market.

The Company is the first company in the world to have developed and commercialized an rhTPO product. Since its launch in 2006, TPIAO has remained the only approved rhTPO product in the People’s Republic of China (the “**PRC**”). TPIAO is manufactured at the Company’s mammalian cell-based production plant in Shenyang, the PRC. TPIAO was recognized as a National Key New Product by four PRC state ministries in 2006 and has been recognized as a National Class I New Drug by the China Food and Drug Administration.

By order of the Board
3SBio Inc.
Mr. LOU Jing
Chairman

Hong Kong, July 27, 2016

As at the date of this announcement, the Board comprises Mr. LOU Jing, Mr. TAN Bo, Ms. SU Dongmei and Mr. HUANG Bin as executive directors; Mr. LIU Dong and Mr. LV Dong as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Mr. MA Jun as independent non-executive directors.

⁽¹⁾ Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 Internet. Lyon, France: International Agency for Research on Cancer; 2013. Available from: <http://globocan.iarc.fr>, accessed on 27/07/2016.